Article
Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies.
Bone - 1 Nov 2014
Lézot Frédéric, Chesneau Julie, Battaglia Séverine, Brion Régis, Castaneda Beatriz, Farges Jean-Christophe, Heymann Dominique, Rédini Françoise
Abstract excerpt
High doses of zoledronic acid (ZOL), one of the most potent inhibitors of bone resorption, are currently evaluated in phase III clinical trials in Europe for the treatment of malignant pediatric primary bone tumors. The impact of such an intensive treatment on the craniofacial skeleton growth is a critical question in the context of patients with actively growing skeleton; in particular, in light of our previous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.